4.7 Review

Human carboxylesterases: a comprehensive review

Journal

ACTA PHARMACEUTICA SINICA B
Volume 8, Issue 5, Pages 699-712

Publisher

INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2018.05.005

Keywords

Human carboxylesterases; CES1; CES2; Substrate preference; Inhibitor spectra; Inducer

Funding

  1. National Key Research and Development Program of China [2016YFC1303900, 2017YFC1700200, 2017YFC1702000]
  2. National Scientific and Technological Major Projects of China [2017ZX09101004]
  3. National Natural Science Foundation of China [81703604, 81773687, 21602219, 81573501, 81473181]
  4. Program of Shanghai Academic/Technology Research Leader [18XD1403600]
  5. Innovative Entrepreneurship Program of High-level Talents in Dalian [2016RQ025]

Ask authors/readers for more resources

Mammalian carboxylesterases (CEs) are key enzymes from the serine hydrolase superfamily. In the human body, two predominant carboxylesterases (CES1 and CES2) have been identified and extensively studied over the past decade. These two enzymes play crucial roles in the metabolism of a wide variety of endogenous esters, ester-containing drugs and environmental toxicants. The key roles of CES in both human health and xenobiotic metabolism arouse great interest in the discovery of potent CES modulators to regulate endobiotic metabolism or to improve the efficacy of ester drugs. This review covers the structural and catalytic features of CES, tissue distributions, biological functions, genetic polymorphisms, substrate specificities and inhibitor properties of CES1 and CES2, as well as the significance and recent progress on the discovery of CES modulators. The information presented here will help pharmacologists explore the relevance of CES to human diseases or to assign the contribution of certain CES in xenobiotic metabolism. It will also facilitate medicinal chemistry efforts to design prodrugs activated by a given CES isoform, or to develop potent and selective modulators of CES for potential biomedical applications. (C) 2018 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available